Alexion has a robust pipeline of product candidates that build on the company's expertise in complement inhibition
and antibody development. The company is evaluating eculizumab – currently indicated for the treatment of patients
with PNH and aHUS (U.S. and EU) – as a potential treatment for patients with other life-threatening and often rare
diseases in which complement activation plays a role. Alexion also is accelerating the development of other innovative
biotechnology product candidates with a focus on serving patients with severe and ultra-rare disorders for which
current treatment options remain inadequate.